Cost-Effectiveness Analysis of rFVIIIFc Versus Contemporary rFVIII Treatments for Patients with Severe Hemophilia A Without Inhibitors in the United States.

ABSTRACT:

Background

A range of treatments for patients with severe hemophilia A (HA) have been developed over the last decade, allowing for reduced frequency of administration and improved outcomes (joint health and breakthrough bleeding rates). While clinically effective, the cost effectiveness of these treatments has not been established.

Objective

This study presents a cost-effectiveness analysis of contemporary rFVIII treatments for severe HA patients without inhibitors.

Methods

A published semi-Markov model was used to compare three different prophylaxis regimens: (1) extended half-life (EHL) recombinant Factor VIII (rFVIII) Fc-fusion protein (rFVIIIFc, Eloctate^®, Sanofi), (2) EHL PEGylated rFVIII (PEG-rFVIII, Adynovate^®, Takeda), and (3) standard ha

SUBMITTER: Bullement A 

PROVIDER: S-EPMC8611150 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature